key: cord-0791928-pwrwrpjr authors: Murer, Luca; Volle, Romain; Andriasyan, Vardan; Petkidis, Anthony; Gomez-Gonzalez, Alfonso; Yang, Liliane; Meili, Nicole; Suomalainen, Maarit; Bauer, Michael; Sequeira, Daniela; Olszewski, Dominik; Georgi, Fanny; Kuttler, Fabien; Turcatti, Gerardo; Greber, Urs F. title: Identification of broad anti-coronavirus chemical agents for repurposing against SARS-CoV-2 and variants of concern date: 2022-01-15 journal: Curr Res Virol Sci DOI: 10.1016/j.crviro.2022.100019 sha: 2a1d535b22d231c1891e41aca2ca7b66131d38fc doc_id: 791928 cord_uid: pwrwrpjr Endemic human coronaviruses (hCoVs) 229E and OC43 cause respiratory disease with recurrent infections, while severe acute respiratory syndrome (SARS)-CoV-2 spreads across the world with impact on health and societies. Here, we report an image-based multicycle infection procedure with α-coronavirus hCoV-229E-eGFP in an arrayed chemical library screen of 5440 clinical and preclinical compounds. Toxicity counter selection and challenge with the β-coronaviruses OC43 and SARS-CoV-2 in tissue culture and human airway epithelial explant cultures (HAEEC) identified four FDA-approved compounds with oral availability. Methylene blue (MB, used for the treatment of methemoglobinemia), Mycophenolic acid (MPA, used in organ transplantation) and the anti-fungal agent Posaconazole (POS) had the broadest anti-CoV spectrum. They inhibited the shedding of SARS-CoV-2 and variants-of-concern (alpha, beta, gamma, delta) from HAEEC in either pre- or post exposure regimens at clinically relevant concentrations. Co-treatment of cultured cells with MB and the FDA-approved SARS-CoV-2 RNA-polymerase inhibitor Remdesivir reduced the effective anti-viral concentrations of MB by 2-fold, and Remdesivir by 4 to 10-fold, indicated by BLISS independence synergy modelling. Neither MB, nor MPA, nor POS affected the cell delivery of SARS-CoV-2 or OC43 (+)sense RNA, but blocked subsequent viral RNA accumulation in cells. Unlike Remdesivir, MB, MPA or POS did not reduce the release of viral RNA in post exposure regimen, thus indicating infection inhibition at a post-replicating step as well. In summary, the data emphasize the power of unbiased, full cycle compound screens to identify and repurpose broadly acting drugs against coronaviruses. In December 2019, a local outbreak of pneumonia caused by an unknown agent was reported in Wuhan (Hubei, China), and soon after the agent was identified as SARS-CoV-2 causing Coronavirus disease 2019 (COVID-19) (1), which has caused more than 210 million PCR positive cases and 5 million deaths (status Nov 10, 2021 , computed by the Johns Hopkins Coronavirus Research Center) (2). The virus continues to spread throughout the world. Although vaccination with mRNA and viral vector therapies clearly limits the severity of SARS-CoV-2 caused disease (3, 4) , evidence emerges that it will not suffice to contain the ongoing pandemics, and incompletely protects humans from severe COVID-19 across all age groups (5) (6) (7) (8) (9) . Infection breakthrough is in part associated with emerging SARS-CoV-2 variants. Variants of concern are more contagious (alpha variant B. Severe COVID-19 is accompanied by respiratory failure, and patients require mechanical ventilation at intensive care units, and are at risk to develop acute respiratory distress syndromes, multiple organ dysfunction syndromes or failures and death (10) . Current treatment options are limited, and include supportive care, and administration of the viral RNA polymerase inhibitor Remdesivir together with corticosteroids to limit inflammatory distress (https://www.covid19treatmentguidelines.nih.gov/therapeutic-management/). Besides the mRNA vaccines, there are just five FDA approved anti-COVID-19 therapies -the repurposed viral polymerase inhibitor Remdesivir (11) , the janus kinase (JAK) 1 and 2 inhibitor Baricitinib blocking proinflammatory syndrome, the anti-S-protein IgG monoclonal antibody LY-CoV555, the anti-SARS-CoV-2 antibody cocktail Casirivimab / Imdevimab, and the monoclonal antibody Actemra blocking the interleukin 6 receptor (https://racetoacure.stanford.edu). Currently, Remdesivir in combination with anti-inflammatory agents, such as the corticosteroid dexamethasone is a broadly used treatment to restrict severe lung inflammation and multiorgan failure upon marked immune cell dysregulation and cytokine storm syndrome (12) . Drug repurposing allows for rapid identification of clinically approved or investigational compounds towards emerging indications. This approach offers a multitude of advantages over de novo drug development (reviewed in 13). Most importantly, candidate compounds have a demonstrated safety record allowing for direct transition to human clinical trials. For example, the ReFrame library comprising some 12,000 compounds was used to screen single round SARS-CoV-2 infections, focussing on virus replication but omitting assembly and egress processes (14) . This yielded compounds inhibiting genome replication and steps upstream of replication, such as MK-4482 (Molnupiravir, nucleoside analog), Nafamostat mesylate (SARS-CoV-2), cells were fixed as described above. Subsequently, the experiments were subjected to immunostaining. Cells were permeabilized with 0.2% Triton-X-100 for 5 min, washed with PBS, incubated with primary antibodies against coronavirus nucleoprotein (Chemicon MAB 9013 for OC43, Rockland 200-401-A50 for SARS-CoV-2) in PBS + 1% bovine serum albumin (BSA) for 1 h, washed and incubated with a secondary antibody in PBS + 1% BSA for 1 h. Cells were then washed again, PBS was replaced with PBS + 0.02% N3 and finally, plates were imaged as described above. Only after the acquisition of images, the content lists were provided to UZH by EPFL to ensure the image analysis was conducted blinded. Compounds were considered hits if the mean GFP intensity signal value of all replicates falls below the mean of all negative control wells minus three times the standard deviation of all negative control wells for that specific readout. Hit lists were combined for all parameters. In the validation experiments, compounds were considered toxic if the mean number of nuclei was lower than the mean number of nuclei of all negative control wells divided by two. H1299 or Huh7 cells (about 20000 per well in a 96-well imaging plate) were treated with indicated concentrations of Remdesivir and MB at 37°C, either alone and in combination resulting in a nine by nine matrix. After about 12h, the cells were infected with hCoV-229E-GFP virus at MOI 0.001 at 33.5°C, fixed with 4% PFA and stained with Hoechst 33342 nuclear dye at 3 d pi. The experiment was performed in triplicate. The resulting plaques were quantified using Plaque 2.0 (24). The plaque number readout was normalized using the maximum number of plaques observed in the well of interest. The inhibitory effect of the drugs was represented as: Synergy of the drugs was assessed using BLISS synergy score calculated and visualized by using the web tool Synergy Finder (http://www.synergyfinder.org) (25). Table S1 . We conducted PCR control measurements with comparable results using probes for either the M or the Pol gene (Nsp12), the latter only present in genomic but not subgenomic RNA (28), thereby ruling out the possibility that the M probe would measure preferentially subgenomic RNA fragments (Table S2) . Bronchial inserts were obtained from a single donor (Epithelix SA, Geneva, Switzerland). Further information about sample collection of biological data points and technical replicates is indicated in the corresponding figure legends. The raw data of the screen are available under doi: 10.17632/47xctms897.1 The funders had no impact on the design of the study, the collection, analyses or interpretation of data, the writing of the report or the publication strategy. Nasal polyp epithelial cells and bronchial epithelial cells were purchased from Epithelix SARL We screened the EPFL BSF-repurposing compound collection, curated and corrected based on information made available by the Broad Institute (32). The overall procedure is depicted in Table S3 ). To conduct the infection screen, the library was arrayed in microscopy grade 384-well assay plates, followed by seeding of Huh7 cells, infection with hCoV-229E-GFP, and high-throughput imaging ( Fig. 2A) . This allowed us to extract image analysis parameters, including total cell count, infected cell count, total GFP intensity and number of infection foci (plaques) (see also To assess the therapeutic potential of the 53 hit compounds EC50 and TC50 values were determined for hCoV-229E-GFP in Huh7 cells by conducting dose-response experiments with concentrations from 1.525 nM to 50 μM. The results are summarized in Table 1 and Table S3 . Thirty nine compounds had an EC50 < 2μM and a therapeutic index (TI) of > 2, as determined (Table 1) . We next generated Huh7, human lung epithelial A549 and human cervical carcinoma HeLa cells expressing ACE2 by lentivirus transduction (Fig. S2 ). These ACE2 transduced cells as well as African green monkey kidney epithelial Vero E6 cells were susceptible to SARS-CoV-2 ( Fig. 3B and Table 1 ). Eleven compounds were effective in two or more cell lines against SARS-CoV-2, and two (Tables 1 and 2, Table S3 ). In the following, we focussed on the systemic compounds. We inhibitor Ro48-8071 involved in cholesterol biosynthesis (42) . However, none of the four preclinical compounds tested was considered further. OTSSP167 and A0001 lacked anti-viral activity, while MLN4924 and Ro48-8071 were toxic in HAEEC (Table S4) . Remarkably, R788-Fostamatinib exhibited no consistent anti-viral effects on SARS-CoV-2 titer release in the apical milieu at 3.3 or 10 µM but gave rise to changes in HAEEC morphology, and therefore was not further considered. In contrast to Fostamatinib, MB, MPA, and POS-treated HAEEC remained morphologically unchanged in both pre-and post-exposure settings, akin to Remdesivir-treated cells, the latter as previously reported (43) . MB, MPA and POS treated inserts displayed robust ciliary beating akin to uninfected cells, whereas exposure to a toxic concentration of MLN4924 strongly impaired ciliary movement ( by RT-qPCR measurements, the genome load increased towards 8 d pi, and was largely unaffected in the post-exposure regimen, unlike Remdesivir-treated cells, which consistently showed 2-3 logs lower genome copies than the DMSO controls ( Fig. S3A-D) . MPA treatment had significant antiviral effects, at both 1 and 10 µM, albeit less pronounced than MB, and with delayed efficacy (Fig. 5A) . Strikingly, the genome copy numbers in the apical supernatant were only mildly reduced by MPA in both pre-and post exposure regimen. Nevertheless, the antiviral effects of both MB and MPA were reproduced in bronchial HAEEC, thus confirming the results in nasal HAEEC (Fig. S4A-D) . POS treatment (20 µM) also showed significant antiviral effects in pre-and post-exposure settings (Fig. 5B, Fig. S5 ). Intriguingly, the reduction of virus titer was more pronounced if POS was added post exposure. We next tested the effects of MB, MPA and POS on SARS-CoV-2 variants of concern. These variants have Table S4 . Together, our results demonstrate broad efficacy of MB and MPA and somewhat lesser effects by POS against seven human coronaviruses, the SARS-CoV-2 'Wuhan' strain, the alpha, beta, gamma, and delta variants as well as the endemic CoV viruses 229E and OC43, by a mechanism distinct from Remdesivir. Individuals suffering from COVID-19 are in need of acute medical treatment with broadly available safe and effective antivirals. In addition, the zoonotic and anthroponotic transmission of coronaviruses from animals to humans and from human to animals (44, 45) (48, 50) . De novo development of antivirals is a lengthy and costly process and insufficient to resolve the current crisis in short terms (51) . Our large scale drug repurposing screen identified broadly acting clinically approved small molecular weight compounds. We took advantage of EPFL's to O-acetylated sialic acid (53) (54) (55) . SARS-CoV and SARS-CoV-2 bind to ACE2 (56) . Upon furin cleavage of the S-glycoprotein, the latter contacts neuropilin for efficient entry (57, 58) . Hence, the compounds that we identified likely target host functions in virus progeny formation, egress from infected cells or transmission to neighboring cells. We confirmed this notion for MB, MPA and POS, which did not block the uptake of viral RNA but reduced the levels of replicated viral genomes in the infected cells. Previous studies had suggested that MB inhibits SARS-CoV2 entry in Vero E6 cells ( Remdesivir may be warranted (11, 72) . Endpoints may include survival and blood oxygenation levels, both of which are expected to be enhanced by the combination treatment due to the anti-viral effects of both agents and the potency of MB to treat methemoglobinemia in patients resistant to oxygen therapy. Our screen and follow-up experiments identified MPA as a broad anti-coronavirus inhibitor. Mechanistically, MPA is a non-competitive inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH) involved in guanine biosynthesis (73) . IMPDH interacts with and supports SARS-CoV nonstructural protein 14 (Nsp14), a guanine-N7-methyl-transferase implicated in virus replication and transcription (74) . In addition, MPA leads to a reduction in the levels of the furin protease in human pluripotent stem cell derived lung organoids, and inhibits the entry of S-glycoprotein pseudotyped vesicular stomatitis particles (75) . Furin has a key role in viral pathogenesis and dissemination, and is required for the limited proteolysis of the SARS-CoV-2 S-protein, and S-protein engagement with the neuropilin-1 receptor and virus infectivity, especially neuronal and heart cell infections (57, 58) . (Table S4 ). Ro 48-8071 is a potent inhibitor of oxidosqualene cyclase (OSC) which catalyzes the conversion of monooxidosqualene to lanosterol (93) , and could interfere with positive-strand RNA viruses, including hepatitis C virus (94), poliovirus (95) , and rhinovirus (96) . Collectively, these data suggest that the cholesterol biosynthesis pathway is a potential drug target in SARS-CoV-2 infection. One of our strongest hits in the cell culture screens was MLN4924 (Pevonedistat) with an excellent dose-response profile against hCoV-229E-GFP (EC50 30 nM; TC50 40.39 μM) and considerable inhibition of SARS-CoV-2. It is a promising candidate in retinoblastoma therapy (97) , but unfortunately exhibited toxicity in our HAEEC experiments at low micromolar concentrations (Table S4) Our screen revealed several additional launched compounds already described for their potential to treat COVID-19, including Fostamatinib, Eprinomectin and Betulinic acid. Our top compounds are effective against SARS-CoV-2 Wuhan strain as well as four variants of concern, alpha, beta, gamma, and delta. These variants likely evolved in humans since December 2019, indicating that constant evolution and turnover of the circulating SARS-CoV-2 do not affect the efficacy of our inhibitors in human explant cell cultures. This is distinct from inhibitors targeting the virus directly, which the virus rapidly evades, for example favipiravir. Favipiravir is an RNA mutagen with antiviral effects (112) approved in Japan to treat pandemic influenza virus infections. It has anti-viral effects against SARS-CoV-2 in hamsters (113) , and is in clinical trials against COVID-19 (114) . A recent high-throughput computational protein design protocol identified mutational hotspots in the SARS-CoV-2 RNA polymerase confering favipiravir resistance, and remarkably some of these mutations already exist in SARS-CoV-2 J o u r n a l P r e -p r o o f genomes circulating in humans (115, 116) . This implies that direct anti-viral agents readily face drug-resistant viruses, even before treatment, and likely have limited therapeutic effects. We surmise that host targeting anti-virals, such as the compounds identified in this study will have a higher fitness cost for virus to evade than direct anti-viral agents, akin to a recent study on chemical evolution of rhinovirus (117) . We acknowledge financial support from the Swiss National Science foundation (SNSF) to UFG and GT (31CA30_196177 / 1), the NCCR Chemical Biology supported by the SNSF for purchasing the BSF-EPFL repurposing collection, and a special Coronavirus Research grant from the University of Zurich to UFG. We are grateful to Dr. Adriano Aguzzi and Dr. Simone Hornemann for granting generous access to their BSL3 laboratory. We thank Dr. Volker Thiel and Dr. Nadine Ebert for their kind gifts of hCoV-229E-GFP, SARS-CoV-2 isolate Munich, cell lines, as well as discussions and hands-on information, as well as Dr. Daria Seiler, Jonathan Vesin, Antoine Gibelin and Julien Bortoli for their technical assistance. B) The number of nuclei was assessed based on the nuclear counterstain in the screening setup. In contrast, the PrestoBlue based assay was performed in absence of virus, but all the other parameters were kept the same. The score of the Prestoblue assay was normalized with the positive control set as 1, and the negative control as 0. As a result, there is a negative correlation between the parameters. Viral titer (TCID50/ml) readout (bars) of the samples shown in Fig. 6 , and viral genome equivalents (copies/ml, blue dots). Data represent the means±SEM of two independent replicates. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization Vaccine Breakthrough Infections with SARS-CoV-2 Variants 1.617.2 Delta variant replication, sensitivity to neutralising antibodies and vaccine breakthrough Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients SARS-CoV-2 vaccines Evaluation, and Treatment of Coronavirus (COVID-19) Remdesivir for the Treatment of Covid-19 -Final Report COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology Drug repositioning: identifying and developing new uses for existing drugs Drug repurposing screens identify chemical entities for the development of COVID-19 interventions The FDA-approved drug Nelfinavir inhibits lytic cell-free, but not cell-associated non-lytic transmission of human adenovirus Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing Translation elongation factor eEF1A2 is a novel anticancer target for the marine natural product plitidepsin Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects Cell-to-cell and genome-togenome variability of adenovirus transcription tuned by the cell cycle Virus Infection Variability by Single-Cell Profiling Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia Use of an Adaptive Study Design in Single Ascending-Dose Pharmacokinetics of A0001 (α-Tocopherylquinone) in Healthy Male Subjects An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia Hosts and sources of endemic human coronaviruses SARS-CoV-2 infection in farmed minks, the Netherlands Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease Remdesivir targets a structurally analogous region of the Ebola virus and SARS-CoV-2 polymerases An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir Trends in clinical development timeframes for antiviral drugs launched in the UK, 1981-2014: a retrospective observational study The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro Human aminopeptidase N is a receptor for human coronavirus 229E Crystal structure of NL63 respiratory coronavirus receptorbinding domain complexed with its human receptor Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity Neuropilin-1 is a host factor for SARS-CoV-2 infection Methylene blue inhibits replication of SARS-CoV-2 in vitro Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19 High absolute bioavailability of methylene blue given as an aqueous oral formulation Methylene blue as an antimalarial agent Methylene blue unresponsive methemoglobinemia. Indian journal of critical care medicine: peer-reviewed, official publication of Indian Society of Critical Care Medicine Interactions of methylene blue with human disulfide reductases and their orthologues from Plasmodium falciparum Transcriptional regulation by Nrf2 The endoplasmic reticulum unfolded protein responsehomeostasis, cell death and evolution in virus infections SARS-CoV2-mediated suppression of NRF2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery SARS-CoV-2 infection induces the dedifferentiation of multiciliated cells and impairs mucociliary clearance Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19 Pharmacokinetics and organ distribution of intravenous and oral methylene blue Methylene Blue for Treatment of Hospitalized Covid-19 Patients: A Randomized, Controlled, Open-Label Clinical Trial, Phase 2 IMP dehydrogenase: structure, mechanism, and inhibition Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase Identification of SARS-CoV-2 inhibitors using lung and colonic organoids The emergence of mycophenolate mofetilin dermatology: from its roots in the world of organ transplantation to its versatile role in the dermatology treatment room Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases? Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to Suppress Host Defenses COVID-19: consider cytokine storm syndromes and immunosuppression Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system Remdesivir for the treatment of Covid-19 After 62 years of regulating immunity, dexamethasone meets COVID-19 Lymphocyte-selective antiproliferative and immunosuppressive effects of mycophenolic acid in mice Mycophenolate mofetil modulates differentiation of Th1/Th2 and the secretion of cytokines in an active Crohn's disease mouse model Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet Mycophenolate mofetil in solid-organ transplantation SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7. Molecular pharmacology Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmaniasis In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum 3-oxidosqualene: lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin Threedimensional architecture and biogenesis of membrane structures associated with hepatitis C virus replication Complex dynamic development of poliovirus membranous replication complexes Rhinovirus uses a phosphatidylinositol 4-phosphate/cholesterol counter-current for the formation of replication compartments at the ER-Golgi interface Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy A high-content screen for mucin-1-reducing compounds identifies fostamatinib as a candidate for rapid repurposing for acute lung injury Avermectin derivatives, pharmacokinetics, therapeutic and toxic dosages, mechanism of action, and their biological effects Anti-SARS-CoV natural products with the potential to inhibit SARS-CoV-2 (COVID-19) Activating the Wnt/β-catenin pathway for the treatment of melanoma-application of LY2090314, a novel selective inhibitor of glycogen synthase kinase-3 GSK-3-selective inhibitors derived from Tyrian purple indirubins Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family GSK-3 inhibition by an orally active small molecule increases bone mass in rats Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo The glamour and gloom of glycogen synthase kinase-3 The role of GSK-3 in cancer immunotherapy: GSK-3 inhibitors as a new frontier in cancer treatment Targeting the Coronavirus Nucleocapsid Protein through GSK-3 Inhibition. medRxiv Favipiravir as a potential countermeasure against neglected and emerging RNA viruses Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model Role of favipiravir in the treatment of COVID-19 Interface-based design of the favipiravir-binding site in SARS-CoV-2 RNA-dependent RNA polymerase reveals mutations conferring resistance to chain termination Two years into COVID-19 -Lessons in SARS-CoV-2 and a perspective from papers in FEBS Letters Chemical evolution of Rhinovirus identifies capsid-destabilizing mutations driving low pH-independent genome uncoating Supplemental Movie 1: Ciliary beating in mock-treated, uninfected bronchial HAEEC Bronchial HAEEC grown at ALI were mock-infected (day 0), and left untreated and uninfected Prior to imaging, the apical surface was washed with 200 µl of pre-warmed culture medium at 37°C for 20 min to remove mucus. Cilia beating was recorded 6d pi, in live mode at room temperature with an inverted microscope (Axiovert 135, Zeiss) at 50× magnification Supplemental Movie 2: Ciliary beating in DMSO-treated bronchial HAEEC Prior to imaging, the apical surface was washed with 200 µl of prewarmed culture medium at 37°C for 20 min to remove mucus Zeiss) at 50× magnification. Time span: 20 sec at 20 Hz Supplemental Movie 3: Ciliary beating in Remdesivir-treated bronchial HAEEC Prior to imaging, the apical surface was washed with 200 µl of prewarmed culture medium at 37°C for 20 min to remove mucus Zeiss) at 50× magnification. Time span: 20 sec at 20 Hz Supplemental Movie 4: Ciliary beating in MB-treated bronchial HAEEC Prior to imaging, the apical surface was washed with 200 µl of pre-warmed culture medium at 37°C for 20 min to remove mucus. Cilia beating was recorded 6d pi, in live mode at room temperature with an inverted microscope (Axiovert 135, Zeiss) at 50× magnification. Time span: 20 sec at 20 Hz Prior to imaging, the apical surface was washed with 200 µl of pre-warmed culture medium at 37°C for 20 min to remove mucus. Cilia beating was recorded 6 d pi, in live mode at room temperature with an inverted microscope (Axiovert 135, Zeiss) at 50× magnification Prior to imaging, the apical surface was washed with 200 µl of pre-warmed culture medium at 37°C for 20 min to remove mucus. Cilia beating was recorded 5d pi, in live mode at room temperature with an inverted microscope (Axiovert 135, Zeiss) at 50× magnification Supplemental Movie 7: Ciliary beating in MLN4924-treated nasal HAEEC Nasal HAEEC grown at ALI were inoculated apically with 1,000 FFU of SARS-CoV2 'Wuhan' (day 0), and treated daily with 1 µM MLN4924 in the basolateral medium using a post-infection regimen (1d pi) Mouse monoclonal anti-dsRNA English & Scientific Consulting J2 American Type Cell Culture Cat #VR-1558 Kindly provided by Dr University of Geneva) SARS-CoV2 Beta University of Geneva) SARS-CoV-2 Gamma (NH-RIVM10915/2021) RIVM (through EVaG) Not available any Human: H1299 Kindly provided by Dr Greber Laboratory 2) Identification of five FDA-approved small chemical compounds ready to repurpose against COVID-19.3) MB. MPA, Posaconazole are orally applicable, and preclinically inhibit the production of infectious SARS-CoV-2 and four variants of concern in human airway epithelial explant cultures.4) One of the approved compounds, MPA has anti-inflammatory effects, while another one, MB increases blood oxygenation levels in patients. independent synergy with the RNA-dependent RNA polymerase inhibitor Remdesivir.6) The data advocate a two-pronged strategy for testing of MB and MPA in clinical trials against COVID-19, a concerted anti-viral and an anti-inflammatory arm, with a drug synergy option.J o u r n a l P r e -p r o o f ☐ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☒The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:UFG has been a consultant and stock owner in 3V-Biosciences (now Sagimet Biosciences), a consultant to F. Hoffmann-La Roche Ltd and to Union Therapeutics A/S. The authors filed a patent application on the use of MPA for the treatment of COVID-19 (EP20213904, European Patent Office, University of Zurich).